title: An overview of coagulation disorders in cancer patients.
abstract: A diversity of coagulation disorders in cancer patients arise from tumor-specific growth characteristics, neoangiogenesis with impaired endothelial lining, defective myelopoiesis, hypoproteinemia or metastatic lesions growth with organ dysfunction. Recent investigations have found a clinically relevant correlation of coagulation disorders and tumor growth. These prompted new therapeutic strategies focused on growth factors with the aim to control tumor metastasis, particularly if used for the treatment of micrometastatic disease. However, such treatment may lead to the life threatening coagulation imbalance. A coagulation homeostasis may become further impaired after nonsurgical cancer therapy, especially after preoperative irradiation, which produces lesions precipitating both bleeding and thrombosis. Anticancer chemotherapy may affect liver function and decrease the synthesis of both procoagulation and anticoagulation factors. The most of chemotherapeutic protocols affect platelet synthesis, which arises as a principal dose-limiting side effect. It was observed both during combined systemic chemotherapy and local antitumor therapy. Although the side effects produced by chemotherapy are reversible, endothelial lesions may persist for many years after the anticancer treatment. Instead of cancer patients, there's a growing cohort of patients with nonmalignant diseases who use cytostatics in the perioperative period, and are candidates for surgical procedures not related to their malignant disease, i.e. hernia repair. In this patient population a special attention must be paid to the preoperative evaluation of coagulation status and thromboprophylaxis. This overview reminds the most common coagulation disorders in cancer patients in the perioperative period. It emphasizes the need for proper patient monitoring which may facilitate the diagnostics and treatment of cancer-related coagulation disorders in the perioperative setting.
authors.affiliation: Department of Anesthesiology and ICU, University Hospital Osijek, J. Huttlera 4, 31000 Osijek, Croatia. slavica.kvolik@os.t-com.hr
authors.forename: Slavica
authors.initials: S
authors.lastname: Kvolik
authors.forename: Marko
authors.initials: M
authors.lastname: Jukic
authors.forename: Marko
authors.initials: M
authors.lastname: Matijevic
authors.forename: Ksenija
authors.initials: K
authors.lastname: Marjanovic
authors.forename: Ljubica
authors.initials: L
authors.lastname: Glavas-Obrovac
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use; D001778:Blood Coagulation Disorders / Q000139:chemically induced / Q000209:etiology* / Q000473:pathology; D004211:Disseminated Intravascular Coagulation / Q000209:etiology; D004730:Endothelium, Vascular / Q000473:pathology; D005342:Fibrinolysis; D006801:Humans; D009369:Neoplasms / Q000098:blood supply / Q000150:complications* / Q000188:drug therapy; D009389:Neovascularization, Pathologic / Q000188:drug therapy / Q000209:etiology; D012307:Risk Factors; D013923:Thromboembolism / Q000209:etiology
chemical_list: D020533:Angiogenesis Inhibitors; D000970:Antineoplastic Agents